

Malaysia's First Locally Made Oncology Product for Export to The U.S., Dispatched on 5th of March 2024



We are delighted to announce the dispatch of our Abiraterone Acetate Tablets 250mg & 500mg on March 5th, 2024, marking a significant milestone in Novugen's Milestone. Abiraterone Acetate is the first oncology product 'Made in Malaysia,' following its recent approval from the USFDA for in-house manufacturing at Novugen Oncology plant in Bandar Enstek, Negeri Sembilan, Malaysia, for export to the U.S.

A total of 3 batches, comprising a total of 1,833 bottles of Abiraterone Acetate Tablets, have been dispatched for commercialization in the U.S. market through our US-based office, Novugen Pharma FE LLC (USA). A small ceremony was also organized to celebrate this accomplishment that underscores our unwavering dedication to advancing global healthcare standards.